Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Ptc Therapeutics (PTCT) over the last 13 years, with Q3 2025 value amounting to $177.2 million.

  • Ptc Therapeutics' Change in Acquisitions & Divestments rose 1492.61% to $177.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $683.1 million, marking a year-over-year increase of 7013.45%. This contributed to the annual value of $549.6 million for FY2024, which is 31565.25% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Change in Acquisitions & Divestments of $177.2 million as of Q3 2025, which was up 1492.61% from $110.4 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Change in Acquisitions & Divestments registered a high of $392.1 million during Q1 2021, and its lowest value of $700000.0 during Q3 2021.
  • For the 5-year period, Ptc Therapeutics' Change in Acquisitions & Divestments averaged around $120.9 million, with its median value being $110.5 million (2023).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first crashed by 9974.28% in 2021, then soared by 1196514.29% in 2022.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Change in Acquisitions & Divestments stood at $150.2 million in 2021, then tumbled by 57.89% to $63.2 million in 2022, then skyrocketed by 75.01% to $110.7 million in 2023, then skyrocketed by 133.79% to $258.8 million in 2024, then plummeted by 31.52% to $177.2 million in 2025.
  • Its last three reported values are $177.2 million in Q3 2025, $110.4 million for Q2 2025, and $136.8 million during Q1 2025.